548 related articles for article (PubMed ID: 19356610)
1. Effectiveness of Jeryl Lynn-containing vaccine in Spanish children.
Castilla J; García Cenoz M; Arriazu M; Fernández-Alonso M; Martínez-Artola V; Etxeberria J; Irisarri F; Barricarte A
Vaccine; 2009 Mar; 27(15):2089-93. PubMed ID: 19356610
[TBL] [Abstract][Full Text] [Related]
2. Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak.
Rubin SA; Qi L; Audet SA; Sullivan B; Carbone KM; Bellini WJ; Rota PA; Sirota L; Beeler J
J Infect Dis; 2008 Aug; 198(4):508-15. PubMed ID: 18558869
[TBL] [Abstract][Full Text] [Related]
3. [Mumps epidemic in vaccinated children in West Switzerland].
Ströhle A; Eggenberger K; Steiner CA; Matter L; Germann D
Schweiz Med Wochenschr; 1997 Jun; 127(26):1124-33. PubMed ID: 9312835
[TBL] [Abstract][Full Text] [Related]
4. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population.
Ong G; Goh KT; Ma S; Chew SK
J Infect; 2005 Nov; 51(4):294-8. PubMed ID: 16291282
[TBL] [Abstract][Full Text] [Related]
6. Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study.
Mrozek-Budzyn D; Kiełtyka A; Majewska R
Pediatr Infect Dis J; 2010 May; 29(5):397-400. PubMed ID: 19952979
[TBL] [Abstract][Full Text] [Related]
7. Mumps vaccine performance among university students during a mumps outbreak.
Cortese MM; Jordan HT; Curns AT; Quinlan PA; Ens KA; Denning PM; Dayan GH
Clin Infect Dis; 2008 Apr; 46(8):1172-80. PubMed ID: 18444852
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness of the mumps component of the MMR vaccine: a case control study.
Harling R; White JM; Ramsay ME; Macsween KF; van den Bosch C
Vaccine; 2005 Jul; 23(31):4070-4. PubMed ID: 15950329
[TBL] [Abstract][Full Text] [Related]
9. Measles transmission and vaccine effectiveness during a large outbreak on a densely populated island: implications for vaccination policy.
Marin M; Nguyen HQ; Langidrik JR; Edwards R; Briand K; Papania MJ; Seward JF; LeBaron CW
Clin Infect Dis; 2006 Feb; 42(3):315-9. PubMed ID: 16392073
[TBL] [Abstract][Full Text] [Related]
10. Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England.
Cohen C; White JM; Savage EJ; Glynn JR; Choi Y; Andrews N; Brown D; Ramsay ME
Emerg Infect Dis; 2007 Jan; 13(1):12-7. PubMed ID: 17370510
[TBL] [Abstract][Full Text] [Related]
11. Could the MMR vaccine replace the measles vaccine at one year of age in Egypt?
Abbassy AA; Barakat SS; Abd El Fattah MM; Said ZN; El Metwally HA
East Mediterr Health J; 2009; 15(1):85-93. PubMed ID: 19469430
[TBL] [Abstract][Full Text] [Related]
12. Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks?
Dayan GH; Rubin S
Clin Infect Dis; 2008 Dec; 47(11):1458-67. PubMed ID: 18959494
[TBL] [Abstract][Full Text] [Related]
13. Mumps vaccination coverage and vaccine effectiveness in a large outbreak among college students--Iowa, 2006.
Marin M; Quinlisk P; Shimabukuro T; Sawhney C; Brown C; Lebaron CW
Vaccine; 2008 Jul; 26(29-30):3601-7. PubMed ID: 18539365
[TBL] [Abstract][Full Text] [Related]
14. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations.
Fombonne E; Zakarian R; Bennett A; Meng L; McLean-Heywood D
Pediatrics; 2006 Jul; 118(1):e139-50. PubMed ID: 16818529
[TBL] [Abstract][Full Text] [Related]
15. American Academy of Pediatrics. Committee on Infectious Diseases. Age for routine administration of the second dose of measles-mumps-rubella vaccine.
American Academy of Pediatrics. Committee on Infectious Diseases
Pediatrics; 1998 Jan; 101(1 Pt 1):129-33. PubMed ID: 11345975
[TBL] [Abstract][Full Text] [Related]
16. Non-preventable mumps outbreaks in schoolchildren in Catalonia.
Cardeñosa N; Domínguez A; Camps N; Martínez A; Torner N; Navas E; Salleras L
Scand J Infect Dis; 2006; 38(8):671-4. PubMed ID: 16857613
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine.
LeBaron CW; Bi D; Sullivan BJ; Beck C; Gargiullo P
Pediatrics; 2006 Oct; 118(4):1422-30. PubMed ID: 17015532
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
Vesikari T; Baer M; Willems P
Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
[TBL] [Abstract][Full Text] [Related]
19. Outbreak of mumps in a vaccinated child population: a question of vaccine failure?
Vandermeulen C; Roelants M; Vermoere M; Roseeuw K; Goubau P; Hoppenbrouwers K
Vaccine; 2004 Jul; 22(21-22):2713-6. PubMed ID: 15246601
[TBL] [Abstract][Full Text] [Related]
20. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.
Spoulou V; Giannaki M; Vounatsou M; Bakoula C; Grafakos S
Bone Marrow Transplant; 2004 Jun; 33(12):1187-90. PubMed ID: 15077129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
